Evidence map›Paper›PMID 39694602›Full record

ArticleEuropean journal of heart failure2025

Prediction of new-onset atrial fibrillation in patients with hypertrophic cardiomyopathy using machine learning.

Ree Lu, Heidi S Lumish, Kohei Hasegawa, Mathew S Maurer, Muredach P Reilly, Shepard D Weiner, Albree Tower-Rader, Michael A Fifer, Yuichi J Shimada

Abstract readMulticenter Study
In one paragraph

Article in European journal of heart failure, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers.

0numbers the graph read from it
0cells of the map it votes in
12citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

12 citing papers in PubMed.

  1. Article
  2. Article
  3. Article
  4. Review
  5. Article
  6. Article
  7. Article
  8. Review
  9. Review
  10. Review
  11. Review
  12. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Ree Lu *Division of Cardiology, Department of Medicine, Columbia University Irving Medical Center, New York, NY, USA.
Heidi S Lumish *Division of Cardiology, Department of Medicine, Columbia University Irving Medical Center, New York, NY, USA.
Kohei HasegawaDepartment of Emergency Medicine, Massachusetts General Hospital, Harvard Medical School, Boston, MA, USA.
Mathew S MaurerDivision of Cardiology, Department of Medicine, Columbia University Irving Medical Center, New York, NY, USA.
Muredach P ReillyDivision of Cardiology, Department of Medicine, Columbia University Irving Medical Center, New York, NY, USA.
Shepard D WeinerDivision of Cardiology, Department of Medicine, Columbia University Irving Medical Center, New York, NY, USA.
Albree Tower-RaderCardiology Division, Department of Medicine, Massachusetts General Hospital, Harvard Medical School, Boston, MA, USA.
Michael A FiferCardiology Division, Department of Medicine, Massachusetts General Hospital, Harvard Medical School, Boston, MA, USA.
Yuichi J ShimadaDivision of Cardiology, Department of Medicine, Columbia University Irving Medical Center, New York, NY, USA.

Funding

Clinical and Translational Science AwardUL1TR001873 · NCATS · COLUMBIA UNIVERSITY HEALTH SCIENCES · PI REILLY, MUREDACH P · 2016 to 2025
$99.0M
Proteomics profiling in hypertrophic cardiomyopathy and cardiac event predictionR01HL157216 · NHLBI · COLUMBIA UNIVERSITY HEALTH SCIENCES · PI SHIMADA, YUICHI · 2021 to 2025
$3.5M
Transcriptomics, pathobiology, and cardiac event in hypertrophic cardiomyopathyR01HL168382 · NHLBI · COLUMBIA UNIVERSITY HEALTH SCIENCES · PI Yuichi Shimada · 2023 to 2026
$2.9M
Midcareer Mentoring Award for Patient Oriented Research in Geriatric CardiologyK24AG036778 · NIA · COLUMBIA UNIVERSITY HEALTH SCIENCES · PI MAURER, MATHEW S · 2010 to 2020
$1.6M
Mentored Patient Oriented Research in Cardiometabolic DiseaseK24HL107643 · NHLBI · UNIVERSITY OF PENNSYLVANIA · PI REILLY, MUREDACH P · 2011 to 2020
$1.4M
American Heart Association 15CRP22930001American Heart Association 17MCPRP33670415American Heart Association 18CDA34110245American Heart Association 24GWTDRA1339624American Heart Association 24TPA1289155Columbia University Irving Medical Center Irving Institute for Clinical & Translational Research Precision Medicine Pilot AwardColumbia University Irving Medical Center Marjorie and Lewis Katz Cardiovascular Research PrizeFeldstein Medical FoundationKorea Institute of Oriental Medicine W22005NCATS NIH HHS UL1 TR001873NHLBI NIH HHS K24 HL107643NHLBI NIH HHS R01 HL157216NHLBI NIH HHS R01 HL168382NIA NIH HHS K24 AG036778NIH HHS K24 AG036778NIH HHS K24 HL107643NIH HHS R01 HL157216NIH HHS R01 HL168382NIH HHS UL1 TR001873
6 · The paper itself

Abstract

aimsAtrial fibrillation (AF) is the most common sustained arrhythmia among patients with hypertrophic cardiomyopathy (HCM), leading to increased symptom burden and risk of thromboembolism. The HCM-AF score was developed to predict new-onset AF in patients with HCM, though sensitivity and specificity of this conventional tool are limited. Thus, there is a need for more accurate tools to predict new-onset AF in HCM. The objective of the present study was to develop a better model to predict new-onset AF in patients with HCM using machine learning (ML). METHODS AND

resultsIn this prospective, multicentre cohort study, we enrolled 1069 patients with HCM without a prior history of AF. We built a ML model (logistic regression with Lasso regularization) using clinical variables. We developed the ML model using the cohort from one institution (training set) and applied it to an independent cohort from a separate institution (test set). We used the HCM-AF score as a reference model. We compared the area under the receiver-operating characteristic curve (AUC) between the ML model and the reference model using the DeLong's test. Median follow-up time was 2.1 years, with 128 (12%) patients developing new-onset AF. Using the ML model developed in the training set to predict new-onset AF, the AUC in the test set was 0.84 (95% confidence interval [CI] 0.77-0.91). The ML model outperformed the reference model (AUC 0.64; 95% CI 0.54-0.73; DeLong's p < 0.001). The ML model had higher sensitivity (0.82; 95% CI 0.65-0.93) than that of the reference model (0.67; 95% CI 0.52-0.88). The ML model also had higher specificity (0.76; 95% CI 0.71-0.81) than that of the reference model (0.57; 95% CI 0.41-0.70). Among the most important clinical variables included in the ML-based model were left atrial volume and diameter, left ventricular outflow tract gradient with exercise stress and at rest, late gadolinium enhancement on cardiac magnetic resonance imaging, peak heart rate during exercise stress, age at diagnosis, positive genotype, diabetes mellitus, and end-stage renal disease.

conclusionOur ML model showed superior performance compared to the conventional HCM-AF score for the prediction of new-onset AF in patients with HCM.

Indexed as

Atrial FibrillationCardiomyopathy, HypertrophicMachine LearningAgedFemaleFollow-Up StudiesHumansMaleMiddle AgedProspective StudiesRisk AssessmentRisk FactorsROC CurveAtrial fibrillationHypertrophic cardiomyopathyMachine learningPrediction

Identifiers

PMID39694602
PMCPMC11859767

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.